Early circulating tumour DNA kinetics measured by ultra-deep next-generation sequencing during radical radiotherapy for non-small cell lung cancer: a feasibility study
Abstract Background The evaluation of circulating tumour DNA (ctDNA) from clinical blood samples, liquid biopsy, offers several diagnostic advantages compared with traditional tissue biopsy, such as shorter processing time, reduced patient risk and the opportunity to assess tumour heterogeneity. The...
Main Authors: | G. M. Walls, L. McConnell, J. McAleese, P. Murray, T. B. Lynch, K. Savage, G. G. Hanna, D. Gonzalez de Castro |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-05-01
|
Series: | Radiation Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13014-020-01583-7 |
Similar Items
-
Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer
by: Andrew A. Davis, et al.
Published: (2019-12-01) -
Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma
by: Suman Verma, et al.
Published: (2020-10-01) -
Real‐world efficacy and potential mechanism of resistance of icotinib in Asian advanced non‐small cell lung cancer with EGFR uncommon mutations: A multi‐center study
by: Lei Lei, et al.
Published: (2020-01-01) -
Next-Generation Sequencing Analysis of ctDNA for the Detection of Glioma and Metastatic Brain Tumors in Adults
by: Jianfeng Liang, et al.
Published: (2020-08-01) -
Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer
by: Veldore VH, et al.
Published: (2018-01-01)